These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 27239494)
1. Can agrin cerebrospinal fluid concentration be used as an early biomarker for Alzheimer's disease? Del Campo Milan M; Zuroff L; Jimenez CR; Scheltens P; Teunissen CE Alzheimers Dement (Amst); 2015 Mar; 1(1):75-80. PubMed ID: 27239494 [TBL] [Abstract][Full Text] [Related]
2. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans. Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035 [TBL] [Abstract][Full Text] [Related]
3. Phosphorylated tau-Aβ42 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer's disease in multiplex immunoassay panels of cerebrospinal fluid. Harari O; Cruchaga C; Kauwe JS; Ainscough BJ; Bales K; Pickering EH; Bertelsen S; Fagan AM; Holtzman DM; Morris JC; Goate AM; Biol Psychiatry; 2014 May; 75(9):723-31. PubMed ID: 24548642 [TBL] [Abstract][Full Text] [Related]
4. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model. Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W; J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262 [TBL] [Abstract][Full Text] [Related]
5. Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment. Baldeiras I; Santana I; Leitão MJ; Gens H; Pascoal R; Tábuas-Pereira M; Beato-Coelho J; Duro D; Almeida MR; Oliveira CR Alzheimers Res Ther; 2018 Mar; 10(1):33. PubMed ID: 29558986 [TBL] [Abstract][Full Text] [Related]
6. Correlation between Cerebrospinal Fluid Core Alzheimer's Disease Biomarkers and β-Amyloid PET in Chinese Dementia Population. Xie Q; Ni M; Gao F; Dai LB; Lv XY; Zhang YF; Shi Q; Zhu XX; Xie JK; Shen Y; Wang SC ACS Chem Neurosci; 2022 May; 13(10):1558-1565. PubMed ID: 35476397 [TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal Fluid Levels of Amyloid Beta 1-43 in Patients with Amnestic Mild Cognitive Impairment or Early Alzheimer's Disease: A 2-Year Follow-Up Study. Lauridsen C; Sando SB; Shabnam A; Møller I; Berge G; Grøntvedt GR; Bakken IJ; Salvesen Ø; Bråthen G; White LR Front Aging Neurosci; 2016; 8():30. PubMed ID: 26973507 [TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758 [TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal Fluid Mitochondrial DNA in Rapid and Slow Progressive Forms of Alzheimer's Disease. Podlesniy P; Llorens F; Puigròs M; Serra N; Sepúlveda-Falla D; Schmidt C; Hermann P; Zerr I; Trullas R Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32878083 [TBL] [Abstract][Full Text] [Related]
11. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand. Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431 [TBL] [Abstract][Full Text] [Related]
12. Sexually Dimorphic Association of Circulating Plasminogen Activator Inhibitor-1 Levels and Body Mass Index with Cerebrospinal Fluid Biomarkers of Alzheimer's Pathology in Preclinical Alzheimer's Disease. Eruysal E; Ravdin L; Zhang C; Kamel H; Iadecola C; Ishii M J Alzheimers Dis; 2023; 91(3):1073-1083. PubMed ID: 36565112 [TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Fagan AM; Roe CM; Xiong C; Mintun MA; Morris JC; Holtzman DM Arch Neurol; 2007 Mar; 64(3):343-9. PubMed ID: 17210801 [TBL] [Abstract][Full Text] [Related]
15. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease. Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800 [TBL] [Abstract][Full Text] [Related]
16. Diagnosing Alzheimer's disease: Which dementia screening test to use in elderly Puerto Ricans with mild cognitive impairment and early Alzheimer's disease? Rodríguez-Santiago MA; Wojna V; Miranda-Valentín E; Arnold S; Sepúlveda-Rivera V Alzheimers Dement (Amst); 2024; 16(1):e12554. PubMed ID: 38454965 [TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal Fluid Aβ43 Is Reduced in Early-Onset Compared to Late-Onset Alzheimer's Disease, But Has Similar Diagnostic Accuracy to Aβ42. Lauridsen C; Sando SB; Møller I; Berge G; Pomary PK; Grøntvedt GR; Salvesen Ø; Bråthen G; White LR Front Aging Neurosci; 2017; 9():210. PubMed ID: 28701950 [TBL] [Abstract][Full Text] [Related]